Pharmaxis breathing easier after positive Phase II results
28 September, 2004 by Graeme O'NeillPharmaxis (ASX:PXS) investors will be breathing easy after the company announced a positive result from its Phase II clinical trial of Bronchitol, its lead compound for treating the chronic lung disorder bronchiectasis.
Iliad hits homer with first drug
27 September, 2004 by Graeme O'NeillUnlisted Melbourne drug-development company Iliad Chemicals has reported promising results from a pre-clinical trial of its first anti-cancer drug, developed with its proprietary Multicore drug-synthesis technology.
Peptech ready for growth
24 September, 2004 by Melissa TrudingerPeptech (ASX: PTD) is keenly awaiting the day the Centocor decision is handed down by the arbitrators.
NHMRC sets five-year moratorium on organ xenotransplantation
24 September, 2004 by Renate KrelleThe National Health and Medical Research Council has recommended a five-year moratorium on any clinical research into animal-to-human whole organ transplants in Australia.
GTG in $18m deal with Genzyme
23 September, 2004 by Melissa TrudingerGenetic Technologies (ASX: GTG) has taken the first step in forming a strategic alliance with US-based biotech Genzyme by granting a licence for its non-coding DNA patents that will bring in more than AUD$18 million in revenue over the next 11 years.
Psivida spins out diagnostic specialist
23 September, 2004 by Melissa TrudingerPerth nanotechnology company Psivida (ASX: PSD) has spun out an Australia-based diagnostics company, AION Diagnostics.
Wily scientific tricks trap foxes
22 September, 2004 by Graeme O'NeillDr David Dall, CEO of pest-control company Pestat, took a small, anonymous silver spraycan to last month's BioFestival agbiotech conference in Melbourne.
Peplin granted US patent for its anti-cancer therapeutics
21 September, 2004 by Renate KrelleThe United States Patent and Trademark Office has granted Peplin Biotech (ASX: PEP) a patent protecting the broad anti-cancer activity of its angeloyl-substituted ingenanes - a class of molecules which includes its lead molecule PEP005.
Vet Biotechnology targets equine disease
21 September, 2004 by Renate KrelleAnimal health and stem-cell company Vet Biotechnology has advanced to the starting gate - and is readying to list on the Newcastle Stock Exchange in late October.
New biotechs head for the NSX
21 September, 2004 by Renate KrelleHaving waved goodbye to its first biotech alumnus Living Cell Technologies (ASX:LCT) earlier this year, the Newcastle Stock Exchange is expecting a number of fresh biotech companies to list on the exchange this year.
Rockeby lines up diagnostics for FDA approval
20 September, 2004 by Renate KrelleRockeby biomed (ASX: RBY) has lodged a 501(k) submission for regulatory approval of its systemic candidiasis diagnostic SysCan3 with the United States Food and Drug Administration.
Capital markets still healthy, say analysts
20 September, 2004 by Melissa TrudingerAnalysts say that the IPO market for biotech companies in Australia is healthy right now, and they don't foresee any problems in the near future.
Bionomics sets up US subsidiary
20 September, 2004 by Melissa TrudingerBionomics (ASX: BNO) has set up a US subsidiary to hold intellectual property coming out of its US collaborations.
Early success for Biosignal's anti-bacterial contact lenses
20 September, 2004 by Renate KrelleBiosignal (ASX:BOS) and the Institute for Eye Research Ltd (IER) have reported interim results from recent in vitro trials of contact lenses with permanently attached furanones.
Alchemia gets results with anti-cancer compound
20 September, 2004 by Melissa TrudingerAlchemia (ASX: ACL) will commence the preclinical studies necessary to take its lead anti-cancer compound into human clinical trials after positive results from studies in an animal model of lung cancer.
